Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Prostate Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
31 drugs · 100 active trials
7 drugs · 60 active trials
24 drugs · 406 active trials
Outside the funnel: Withdrawn 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 8 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Anti-PD1 Monoclonal Antibody | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 3, 2026 |
| Telmisartan | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 22, 2024 |
| Venetoclax | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | Apr 14, 2015 |
| Birabresib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Oct 23, 2014 |
| Cobimetinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Apr 1, 2020 |
| Entrectinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Apr 1, 2020 |
| Irinotecan | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2001-12 |
| Sonidegib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2014-04 |
| Vemurafenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Apr 1, 2020 |
| Alectinib | Phase 1 | Early Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 30, 2023 |
| Alpelisib | Phase 1 | Early Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 30, 2023 |
| Alvespimycin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-07 |
| Anastrozole | Phase 1 | Early Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 30, 2023 |
| Belinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 4, 2021 |
| Bendamustine | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 15, 2025 |
| Dactolisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-09 |
| Enasidenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| FOLFOX Regimen | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 15, 2013 |
| Ganitumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-10 |
| Idelalisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Imatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Leucovorin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Lonafarnib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2006-01 |
| Lorlatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Mitotane | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-09 |
| PI3Kbeta Inhibitor AZD8186 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 24, 2018 |
| Picoplatin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-04 |
| Pidnarulex | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 21, 2022 |
| Ponatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Regorafenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Retifanlimab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 3, 2021 |
| Rituximab | Phase 1 | Early Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-07 |
| Vistusertib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2014-10 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.